Hematologic Disorders Education Center

Hematological disorders present an enormous set of challenges for clinicians. Healthcare providers are thankful that the treatment alternatives for these disorders are improving at a significant rate and that patient outcomes are improving as well.

The challenge for many clinicians is to keep track of the new pharmacologic approaches to treating hematological disorders. This website has been designed as a resource center for hematologists, oncologists, and other healthcare providers who are involved in the care of these patients.

After Progression on Ruxolitinib, BETi Provides Significant Benefit for Myelofibrosis

After Progression on Ruxolitinib, BETi Provides Significant Benefit for Myelofibrosis

In a phase II study, a bromodomain and extraterminal protein inhibitor (BETi) reduced anemia, spleen volume and symptoms in myelofibrosis patients who had progressed on ruxolitinib...
Reanalysis Confirms Benefit of Fedratinib in MF Patients after Ruxolitinib Failure

Reanalysis Confirms Benefit of Fedratinib in MF Patients after Ruxolitinib Failure

Only one drug, the JAK2 inhibitor ruxolitinib, has received U.S. Food and Drug Administration approval for treatment of myelofibrosis, a life-threatening myeloproliferative neoplasm. Patients who experience relapse or become refractory or intolerant of that drug currently have few options...
ASCO: Nearly 80% Response to Ivosidenib + Azacitidine in IDH1 mutated-AML

ASCO: Nearly 80% Response to Ivosidenib + Azacitidine in IDH1 mutated-AML

The combination of ivosidenib and azacitidine received breakthrough therapy designation for treatment of newly diagnosed IDH1-mutated acute myeloid leukemia (AML) from the FDA in March based on preliminary results of a phase I/II trial...
Pesticide Exposure Linked to Worse Outcomes in Diffuse Large B-Cell Lymphoma

Pesticide Exposure Linked to Worse Outcomes in Diffuse Large B-Cell Lymphoma

Diffuse large B-cell lymphoma patients exposed to pesticides on the job have worse overall survival (OS) and event-free survival and are less likely to respond to treatment...
Should Cytoreductive Therapy Start Sooner in PV and ET?

Should Cytoreductive Therapy Start Sooner in PV and ET?

Treatment of the myeloproliferative neoplasms polycythemia vera (PV) and essential thrombocythemia (ET) generally focuses on reducing the risk of thrombosis and relieving disease symptoms...

Loading...